
Colorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic alterations that can be associated with resistance to KRAS G12C inhibitors, despite no prior treatment with this therapy, according to the results from a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR). The article is titled “Identification of Candidate Alterations Mediating KRASG12C Inhibitor Resistance in Advanced Colorectal and Pancreatic Cancers.” “The KRAS pathway plays a crucial role in cell biology by regulating cell growth, proliferation, differentiation, and survival,” said Hao Xie, MD, PhD, senior author of the study and a medical oncologist at the Mayo Clinic Comprehensive Cancer Center. “While KRAS signaling is tightly regulated in normal cells, mutations that lead to constantly active signaling, such as KRAS G12C, can lead to cancer progression. Such KRAS mutations are major drivers in many types of cancers, and are also linked to poor prognosis and chemotherapy resistance.”
